Improvements in endoscopic features of fibrosis after anti-inflammatory treatment have also been described; recently, the benefit of Dupilumab (a monoclonal antibody that blocks the heterodimeric receptor common for IL-4 and IL-13) on severe, refractory, and fibrostenotic EoE was assessed. The gene discussed is IL13; the disease is eosinophilic esophagitis.